Flushing
10
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (10)
ALDH2 Genetic Testing in East Asian Community
Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea
Treatment of Asian Flushing Syndrome With Topical Alpha Agonists
Effects of Psyllium on Niacin Tolerability
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
Endpoint Validation Study (0524A-015)
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)
Alternative Options to Minimize Niacin-Induced Flushing
Role of Prostaglandins on Niacin-Induced Flushing